[go: up one dir, main page]

DE20221159U1 - Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate - Google Patents

Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate Download PDF

Info

Publication number
DE20221159U1
DE20221159U1 DE20221159U DE20221159U DE20221159U1 DE 20221159 U1 DE20221159 U1 DE 20221159U1 DE 20221159 U DE20221159 U DE 20221159U DE 20221159 U DE20221159 U DE 20221159U DE 20221159 U1 DE20221159 U1 DE 20221159U1
Authority
DE
Germany
Prior art keywords
fentanyl
therapeutic system
transdermal therapeutic
analgesics
analogous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE20221159U
Other languages
German (de)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34105417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE20221159(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10141650A external-priority patent/DE10141650C1/en
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Priority to DE20221159U priority Critical patent/DE20221159U1/en
Publication of DE20221159U1 publication Critical patent/DE20221159U1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

In a transdermal therapeutic system (TTS) comprises a matrix layer based on polyacrylate (I) and containing fentanyl as active agent (A), a backing layer impermeable to (I) and a protective layer to be removed before use, (I) is self-adhesive, is free of carboxy groups and has a saturation solubility for fentanyl of 3-20 wt. % and the (A)-containing layers have at least 80 wt. % of their (A) content in molecular dispersed solution form.
DE20221159U 2001-08-24 2002-07-10 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate Ceased DE20221159U1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE20221159U DE20221159U1 (en) 2001-08-24 2002-07-10 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10141650A DE10141650C1 (en) 2001-08-24 2001-08-24 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
DE20221159U DE20221159U1 (en) 2001-08-24 2002-07-10 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
EP02762336A EP1418894B1 (en) 2001-08-24 2002-07-10 Transdermal therapeutic system with fentanyl

Publications (1)

Publication Number Publication Date
DE20221159U1 true DE20221159U1 (en) 2005-04-07

Family

ID=34105417

Family Applications (4)

Application Number Title Priority Date Filing Date
DE20221161U Ceased DE20221161U1 (en) 2001-08-24 2002-07-10 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
DE20221159U Ceased DE20221159U1 (en) 2001-08-24 2002-07-10 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
DE20221160U Ceased DE20221160U1 (en) 2001-08-24 2002-07-10 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
DE20221087U Ceased DE20221087U1 (en) 2001-08-24 2002-07-10 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE20221161U Ceased DE20221161U1 (en) 2001-08-24 2002-07-10 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE20221160U Ceased DE20221160U1 (en) 2001-08-24 2002-07-10 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
DE20221087U Ceased DE20221087U1 (en) 2001-08-24 2002-07-10 Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate

Country Status (1)

Country Link
DE (4) DE20221161U1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate

Also Published As

Publication number Publication date
DE20221161U1 (en) 2005-04-07
DE20221087U1 (en) 2005-01-20
DE20221160U1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
DE50209364D1 (en) Transdermales therapeutisches system mit fentanyl
AU7253501A (en) Transdermal therapeutic system for highly dispersed silicon dioxide
PH31473A (en) Transdermal therapeutic system comprising galanthamine as active component.
IL165918A0 (en) Improved transdermal delivery system for the administration of rotigotine
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
WO2001068060A3 (en) Stabilised oversaturated transdermal therapeutical matrix systems
CO5640120A2 (en) FORMULATION AND METHODS FOR THE TROMBOCITEMIA TREATMENT
IL165917A0 (en) Improved transdermal delivery system
AU2108300A (en) Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids
HU900199D0 (en) Process for production of surface therapic system comprising 5-fluoruracil as active ingredient
AU1013202A (en) Occlusive transdermal therapeutic system with a non-occlusive backing layer
DE20221160U1 (en) Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
AU2001230193A1 (en) Transdermal therapeutic system for the administration of zaleplon
BRPI0011135B8 (en) transdermal therapeutic delivery system containing neuroleptic agent
KR100387397B1 (en)
MD940311A (en) Transdermal therapeutic system for administering physostigmin thro-ugh the skin, and method of producing thereof

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20050512

R150 Utility model maintained after payment of first maintenance fee after three years

Effective date: 20050729

R197 New subsequently filed claims on ip dossier
R165 Request for cancellation or ruling filed
R151 Utility model maintained after payment of second maintenance fee after six years

Effective date: 20081007

R152 Utility model maintained after payment of third maintenance fee after eight years

Effective date: 20101002

R071 Expiry of right
R071 Expiry of right
R443 Decision by department
R168 Utility model cancelled